Zolistra 4mg inj

Zolistra 4mg inj About

Zolistra 4mg contains the active substance Zoledronic Acid. It belongs to the group of substances called bisphosphonates. It is used to reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumor. Tumors can accelerate normal bone change in such a way that the release of calcium from bone is increased. This condition is known as tumor-induced hypercalcemia (TIH). It is also used to prevent bone complications in adult patients with multiple myeloma and bone metastases from solid tumors (spread of cancer from the primary site to the bone), in addition to standard cancer therapy.Zolistra 4mg is also indicated to prevent or treat osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause. It is also used to treat osteoporosis in men. It is used to treat Pagets disease of bone (a condition in which the bones are soft and weak and may be deformed, painful, or easily broken). Other uses include treating or preventing osteoporosis in men and women taking glucocorticoids (a corticosteroid medication that may cause osteoporosis).Do not take this injection if you are allergic to zoledronic acid, another bisphosphonate, or any other ingredients of this medicine and if you are pregnant or breastfeeding. Before initiating the treatment, inform your physician if you have kidney or liver problems, bone diseases, pain, swelling, or jaw numbness. This medicine is not recommended for use in adolescents and children below the age of 18 years. Zolistra 4mg is not cancer chemotherapy and will not slow or stop the spread of cancer. However, it can be used to treat bone diseases in patients with cancer.

Comprehensive Bone Health Support

Zolistra 4mg Injection targets various bone conditions, including osteoporosis, bone metastases, Pagets disease, and malignancy-related hypercalcemia. As an allopathic prescription medicine, it offers substantial therapeutic benefits for adult patients needing effective bone resorption inhibition and antineoplastic support.


Safe and Regulated Administration

The injection is for intravenous use only and must be diluted before administration. It is prescribed and prepared by healthcare professionals to ensure patient safety. The medicine is provided in a single vial per box, ensuring accurate dosing and minimal waste.


Quality Assurance and Regulatory Compliance

Zolistra is manufactured and marketed in compliance with strict regulatory guidelines, including DCGI approval. It is produced under the supervision of Zolon Healthcare Pvt. Ltd., ensuring consistent quality and pharmaceutical standards for safe use and effective results.